Purpose of this Study
We are doing this study to find out if an experimental drug called navtemadlin (the study drug) is a safe and effective option for people with myelofibrosis (MF). We want to know how well it works when it is combined with ruxolitinib for people who did not get the desired results from ruxolitinib on its own.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with PMF, post-PV MF, or post-ET MF
- Received previous treatment with ruxolitinib and did not have an optimal response
- Have not received previous treatment with any of the following: JAK inhibitor, BCL-XL, BET, MDM2, PI3K, PIM, XPO1 inhibitors; or any p53-directed therapy
What is Involved?
Description
If you choose to join this study and are found to be eligible after a brief screening period, you will begin by taking ruxolitinib on its own for 18-24 weeks. If you continue to be eligible after this period, you will get a random assignment to 1 of 2 groups:
- Group 1: If you are in this group, you will take 240mg dose of the study drug once per day for 7 days (Days 1-7) followed by 21 days of not taking the study drug. You will continue to take ruxolitinib daily at the dose determined by your doctor. Each of these 28-day periods is called a "cycle."
- Group 2: If you are in this group, you will take a dose of placebo (inactive substance that has no drug in it) once per day for 7 days (Days 1-7) followed by 21 days of not taking it. You will continue to take ruxolitinib daily at the dose determined by your doctor.
Study Details
Full Title
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Principal Investigator
Lindsay
Rein
Protocol Number
PRO00116041
NCT ID
NCT06479135
Phase
III
Enrollment Status
Pending Open to Enrollment